

Special Issue

Advances and Research Priorities for Metastatic- Hormone-Resistant Prostate Cancer

Message from the Guest Editor

This Special Issue will cover the advances and research priorities for metastatic-hormone-resistant prostate cancer. It will include the sequencing of combination therapies, highlighting novel molecular targets such as DDL3 and the emerging use of PARP inhibitors and radiopharmaceuticals as a standard of care treatment options. The Special Issue will also adopt the precision oncology viewpoint and highlight the role of ctDNA for real-time treatment personalization and monitoring. Papers on novel theragnostics and PSMA-targeted therapies are welcome in addition to ones highlighting the role of radiation therapy in hormone-resistant disease. Lastly, the Special Issue will include the need for a clinical trial design that investigates symptom and quality of life (QOL) outcome measures. Additionally, papers focused on understanding the real-world effectiveness and patient-centered benefits of new therapies are welcome. I look forward to receiving your contributions.

Guest Editor

Dr. Bassel Nazha

Department of Hematology and Medical Oncology, Emory University
School of Medicine, Atlanta, GA, USA

Deadline for manuscript submissions

closed (31 May 2025)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/216479

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)